Help
protect your adult predialysis and dialysis patients against
hepatitis B with RECOMBIVAX HB® [Hepatitis
B Vaccine (Recombinant)]
Dosing schedules for RECOMBIVAX HB and Engerix-Bb, 2 for
adult predialysis and dialysis patients
|
|
|
| |
- RECOMBIVAX HB Dialysis Formulation
is indicated for vaccination of adult
predialysis and dialysis patients
against infection caused by all known
subtypes
of hepatitis B virus.
Select
Safety Information
- RECOMBIVAX
HB Dialysis Formulation is contraindicated
in the presence of hypersensitivity
to
yeast or
any component of the vaccine. Patients
who develop symptoms suggestive
of hypensensitivity
after an injection with RECOMBIVAX
HB Dialysis Formulation should
not receive further injections
of the
vaccine.
- In a group of studies involving
healthy adults, the most frequent
complaints (>1% of injections)
in individuals receiving RECOMBIVAX
HB included injection-site reactions,
fatigue/weakness,
headache,
fever
(>100°F), malaise,
nausea, diarrhea, pharyngitis, and
upper respiratory infection.
- Predialysis and dialysis patients
respond less well to hepatitis B
vaccines than do healthy individuals,
however, vaccination of adult patients
early in the course of their renal
disease produces higher seroconversion
rates than vaccination after dialysis
has been initiated.
- A booster dose or revaccination
with RECOMBIVAX HB Dialysis Formulation
may be considered in predialysis/dialysis
patients in the anti-HBs level is
less than 10 mlU/mL.
- As with any vaccine, vaccination
with RECOMBIVAX HB may not result
in seroprotection of all vaccinees.
|
RECOMBIVAX HB — Specifically formulated
for your adult dialysis patients
- Three 40 mcg/1.0 mL doses (0, 1,
and 6 months)
- Specific CPT® c Code
90740
- The CDCd recommends
that the need for booster doses of
vaccine should be assessed by annual
antibody testing and a booster dose
given when antibody levels decline
to <10 mIU/mL.1
For reimbursement
questions, call the Merck Vaccine Reimbursment
Support Center
at 1-800-REIMBVAX (1-800-734-6282).
Before administering RECOMBIVAX HB,
please read the Prescribing
Information.
References:
1. Centers for Disease Control
and Prevention. Recommendations for
preventing transmission of infections
among chronic hemodialysis patients.
MMWR. 2001;50(RR-5):1–43
2. Engerix-B®. (Package
insert) Research Triangle Park, NC.
GlaxoSmithKline; 2005.
RECOMBIVAX HB is a registered
trademark of Merck & Co., Inc.
-HBV
|
|
|
|
|
